Bielefeld

• A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major d … Not authorised
  2022-502185-24-00 5 Schizophrenia, schizoaffective disorder, schizophreniform disorder, ma
• A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat … Pending
  2022-502365-26-00 5 Asthma
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending
  2024-517133-40-00 5 newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
• Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending
  2024-517295-37-00 5 low and intermediate risk neuroblastoma
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Urinary Bladder Neoplasms
• A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures Recruiting
  2025-524038-24-00 5 2026-05-22 Focal Epilepsy
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• EMPEROR: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome Recruiting
  2024-519555-28-00 5 2026-03-18 Dravet syndrome
• Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke Recruiting
  2025-521260-35-00 6 2025-11-07 acute ischemic stroke and atrial fibrillation (AF)
• A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant … Recruiting
  2024-516794-70-00 4 2025-11-03 Metastatic non-squamous non-small cell lung cancer
• A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici … Recruiting
  2024-516792-32-01 4 2025-07-18 Metastatic non-squamous non-small cell lung cancer
• An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting
  2024-511166-36-00 5 2025-06-13 Moderate to Severe Plaque Psoriasis
• Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting
  2024-514499-42-00 5 2025-03-12 Refractory Partial Onset Epilepsy
• A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for bipolar depression compared … Recruiting
  2023-506605-19-00 5 2025-02-11 Bipolar depression
• A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for schizophrenia compared to t … Recruiting
  2023-506602-39-00 6 2024-08-01 schizophrenia, schizoaffective disorder, schizophrenifom disorder
• A study to learn how safe fenfluramine is, how well it works, and how it moves through the bloodstream in infants with Dravet syndrome Recruiting
  2022-502359-75-00 5 2024-07-03 Dravet syndrome
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting
  2023-507402-13-00 5 2024-04-03 Multiple myeloma
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting
  2022-502286-16-00 5 2023-10-27 Primary Generalized Tonic-Clonic Seizures
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in … Recruiting
  2022-501152-28-00 4 2022-12-21 Breast Cancer
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenflurami … Recruiting
  2024-518520-77-00 4 2021-11-24 Myclonic-astatic epilepsy
• A clinical trial to learn more about the effects of GIA632 in people with the most common type of vitiligo Recruiting
  2025-522301-37-00 4 2026-06-24 Nonsegmental vitiligo

Showing 1–24 of 141 trials